Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA comments on identity testing

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association requests a 60-day extension to the comment period for FDA's interim final rule on a petition to request exemption from 100% identity testing of dietary ingredients in a letter to FDA Aug. 9. "CHPA and its members feel that additional time is needed to adequately respond to the Federal Register notice," the association notes. The IFR was published June 25 and will be effective Aug. 24 (1"The Tan Sheet" July 23, 2007, p. 3). In a separate same-day filing, the trade group also requests a 60-day extension of the comment period for FDA's draft guidance for industry on an evidence-based review system for the scientific evaluation of health claims. The group feels "additional time is needed to adequately prepare" its comments; if the agency grants CHPA's request, the new comment deadline would be Nov. 6...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel